CFON-026
CFON-026 is a selective, orally active and non-covalent BTK inhibitor with an IC50 of 0.27 nM. CFON-026 has significant antitumor activity against wild-type BTK (TMD8 and REC-1) and all clinically relevant BTK resistance mutations (BTK C481S, T474I, L528W and V416L) . CFON-026 induces complete tumor regression in TMD8 xenograft mice model. CFON-026 can be used for research of hematological cancers like chronic lymphocytic leukemia and waldenström macroglobulinemia[1].
Product Specifications
CAS Number
2941611-57-8
UNSPSC
12352005
Target
Btk
Related Pathways
Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
NC1=NC=C2/C=C/CCCCCC(N[C@@H]3CCC[C@@H](C4=NC(C5=CC=C(C(NC6=CC(C#N)=CC=N6)=O)C=C5)=C1N24)C3)=O
Molecular Formula
C33H34N8O2
Molecular Weight
574.68
References & Citations
[1]Mil Y V, et al.151 (PB139) : CFON-026, a best-in-class macrocyclic non-covalent inhibitor of BTK (WT) and all clinically relevant BTK resistance mutations[J].European Journal of Cancer, 2024, 211.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
